Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149048 For therapy of hyperproliferative disorder in a mammal
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149046 Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof
08/07/2003US20030149043 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
08/07/2003US20030149040 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149036 Substituted benzothiazole amide derivatives
08/07/2003US20030149035 For therapy and prophylaxis of infections by herpesviruses
08/07/2003US20030149034 Indazoles substituted with1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
08/07/2003US20030149024 For therapy of central nervous system disorders such as diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia
08/07/2003US20030149020 For therapy or prophylaxis of obesity, type II diabetes, or disorders of the central nervous system
08/07/2003US20030149019 For therapy or prophylaxis of obesity, type II diabetes, or disorders of the central nervous system
08/07/2003US20030149018 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149003 Functionalized stilbene derivatives as improved vascular targeting agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148990 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148974 Antisense modulation of akt-3 expression
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148958 For therapy and prophylaxis of muscular dystrophy
08/07/2003US20030148957 Corticotropin releasing factor 2 receptor agonists
08/07/2003US20030148956 For therapy and prophylaxis of muscular dystrophy
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148941 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
08/07/2003US20030148517 Preparation and compositions for antrodia camphorata mycelium biologically active material
08/07/2003US20030148514 Human embryonic germ cell line and methods of use
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030148458 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/07/2003US20030148446 Acute neuronal induced calcium binding protein type 1 ligand
08/07/2003US20030148408 Compositions and methods for the diagnosis and treatment of tumor
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148378 Phosphodiesterase 10
08/07/2003US20030148306 Aggrecanase molecules
08/07/2003US20030148264 PDZ (PSD-95/Discs large/ZO-I) domains, (PSD-95 = post-synaptic density protein-95); PDZ proteins involved in assembling ion channels and other transmembrane receptors, at specialized subcellular sites such as tight junctions
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147979 Ligand for peroxisome proliferator-activated receptor
08/07/2003US20030147966 Nanoparticle delivery vehicle
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147887 B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
08/07/2003US20030147884 Administering a breast cancer patient (caused by human ErbB2 oncogene which codes a transmebrane glycoprotein receptor related to epidermal growth factor receptor, is overexpressed) an anti ErbB2 antibody and a drug
08/07/2003US20030147883 Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
08/07/2003US20030147871 An immunotherapy by administering two engineered mammalian cells that each expresses IL-12 and IL-18 interleukins; synergistic response; antitumor treatment
08/07/2003US20030147862 Administering a colony stimulating factor and/or a nucleic acids encoding the factor; treating a vascular tumor
08/07/2003US20030147844 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials
08/07/2003CA2514518A1 Process for the preparation of a nutrient formulation
08/07/2003CA2475003A1 Double-stranded oligonucleotides
08/07/2003CA2474958A1 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003CA2474910A1 Oligonucleotide compositions with enhanced efficiency
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474835A1 Immediate release dosage forms containing solid drug dispersions
08/07/2003CA2474821A1 Anti-viral compounds
08/07/2003CA2474788A1 Compositions and methods for modulating connexin hemichannels
08/07/2003CA2474759A1 Gene for peripheral arterial occlusive disease
08/07/2003CA2474723A1 Bioactive keratin peptides
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474616A1 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003CA2474593A1 N, n'-dimethylated n-confused porphyrins
08/07/2003CA2474590A1 Treatment of male sexual dysfunction
08/07/2003CA2474571A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
08/07/2003CA2474497A1 Compositions and methods related to tim-3, a th1-specific cell surface molecule
08/07/2003CA2474447A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003CA2474434A1 Condensed heterocyclic compounds
08/07/2003CA2474433A1 Arylsulfonamidobenzylic compounds
08/07/2003CA2474316A1 Kappa-pviia-related conotoxins as organ protectants
08/07/2003CA2474277A1 2,4-pyrimidinediamine compounds and their uses
08/07/2003CA2473990A1 Modulation of type ii.beta. phosphoinositide phosphate kinase
08/07/2003CA2473984A1 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
08/07/2003CA2473810A1 Fgfr agonists
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473169A1 Compounds that inhibit factor xa activity
08/07/2003CA2473164A1 Novel compounds that inhibit factor xa activity
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2472342A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003CA2472103A1 Transmucosal delivery of proton pump inhibitors
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2465265A1 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333274A2 Up-converting reporters for biological and other assays using laser excitation techniques
08/06/2003EP1333094A2 Human telomerase catalytic subunit
08/06/2003EP1333034A1 Use of angiotensin II analogs in tissue repair
08/06/2003EP1333026A1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis
08/06/2003EP1333025A1 Cyanopyrrolidine derivatives
08/06/2003EP1333024A1 Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof
08/06/2003EP1333022A2 Compounds containing derivatives of cyclopentane and their use to stimulate skin peeling
08/06/2003EP1332673A1 Method of controlling proliferation and differentiation of stem and progenitor cells
08/06/2003EP1332229A1 Method for screening agents capable of treating obesity
08/06/2003EP1332206A1 Recombinant alpha-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
08/06/2003EP1332152A1 Peptide ligands for prostate specific antigen
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332147A1 Thieno[2,3-c isoquinolines for use as inhibitors of parp
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332139A2 Anticancer agents based on regulation of protein prenylation
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
1 ... 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 ... 1564